---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-098637"
form_type: "8-K"
ticker: null
cik: "0001711933"
company_name: "Akoya Biosciences, Inc."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:28:56.466665+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Akoya Biosciences amends bylaws to adopt Universal Proxy Rules and DGCL updates

## Summary
- Enhanced disclosure requirements for stockholder director nominations and other proposals.
- Requires stockholders to represent intent to solicit proxies under Rule 14a-19 for non-company nominees.
- Company will disregard nominations if stockholder fails to comply with Rule 14a-19 requirements.
- Prohibits placeholder nominees; white proxy card reserved exclusively for the Board.
- Updates stockholder list provisions to reflect recent Delaware General Corporation Law amendments.

## SEC filing metadata
- accession: 0001104659-23-098637
- form_type: 8-K
- cik: 0001711933
- company_name: Akoya Biosciences, Inc.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711933/000110465923098637/0001104659-23-098637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711933/000110465923098637/tm2325584d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-098637
- JSON: https://secwatch.observer/filing/0001104659-23-098637.json
- Plain text: https://secwatch.observer/filing/0001104659-23-098637.txt

## Key facts
- Governance Changes
  Akoya Biosciences, Inc.: Amended and restated bylaws to adopt Rule 14a-19 (Universal Proxy Rules), reflect recent changes to Delaware General Corporation Law, and make other updates (effective 2023-08-31).
  - Change: bylaw amendment
  - Effective: 2023-08-31
  source text: On August 31, 2023, in connection with the adoption of Rule 14a-19 (the “Universal Proxy Rules”) under the Securities Exchange Act of 1934, as amended, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of Akoya Biosciences, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711933/000110465923098637/0001104659-23-098637-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.